Barry Greene, Sage CEO

Sage touts pos­i­tive ear­ly sig­nals in Alzheimer's. Will they be able to re­peat it in a blind­ed study?

Sage Ther­a­peu­tics on Fri­day un­corked what it sees as some pos­i­tive — al­beit ear­ly, and un­blind­ed — da­ta sug­gest­ing its lead neu­ropsy­chi­atric drug led to im­prove­ments in Alzheimer’s pa­tients. Now the re­al test will be see­ing if those re­sults hold up in a larg­er, blind­ed group.

“The study was de­signed first and fore­most for safe­ty, tol­er­a­bil­i­ty and PK,” Aaron Koenig, Sage’s VP of ear­ly clin­i­cal de­vel­op­ment, told End­points News. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.